enzymology enzyme inhibition &therapeutic uses
TRANSCRIPT
Enzymology :Types of Enzyme inhibition & Therapeutic uses
Dr. Rohini C Sane
Enzyme inhibitionEnzyme inhibition
• An Inhibitor –a chemical agent inhibiting /poisoning enzyme
Types of Enzyme inhibition
1. Irreversible Enzyme inhibition
2. reversible Enzyme inhibition
Classification of enzyme inhibition
NO PRODUCT FORMATION
Comparison of competitive and non-competitive enzyme inhibition
Allosteric Regulation
Change of three dimensionalof enzyme by Allosteric inhibitor & activator
Irreversible inhibition• Irreversible inhibitor : destroys a functional group on enzyme
necessary for catalytic activity
• eg Di Isopropyl Fluorophosphate(DFP ) inhibits Acetyl choline esterase
• Iodoacetamide inhibits OH group of serine ,SH group of Cysteine ,Imidazole group of Histidine
DFP – inhibits Serine Proteases such as Acetyl Choline Esterase , Trypsin ,Chymotrypsin ,Elastase
BAL –BRITISH ANTI LEVISITE- Antidote for HEAVY METALS
CYANIDE –Cytochrome Oxidase
FLUORIDE –inhibits Enolase ( removes Mg ⁺⁺/Mn⁺⁺ from the active site OF enzymes
Irreversible inhibition of enzymes
Neurotransmission at synaptic junction by neurotransmitters
Irreversible inhibition of Acetyl Choline Esterase
Malathione – an insecticide
Inhibition of Neurotransmission at synaptic junction by inhibitors of neurotransmitters-Donepezil
Irreversible inhibition of enzymes with SH group -by Iodoacetamide
enzymes with SH group + Iodoacetamide
reversible inhibition of enzymes with Chemically modified enzyme ( inactive )
Allosteric Regulation a) Allosteric inhibitor b) Allosteric activator
Allosteric Regulation a) Allosteric inhibitor b) Allosteric activator
Allosteric Regulation a) Allosteric inhibitor-binds to anallosteric site on enzyme &induces conformation change preventingSubstrate to bind to an active site on enzyme .Product formation inhibited .
Allosteric Regulation a) Allosteric inhibitor-
three dimensional change in enzyme molecule &an active site of enzyme deformed.
Allosteric & covalent modulation
Activation of manyenzymes involve
Phosphorylation of enzyme molecule by Protein Kinases.Deactivation of many enzymes is facilitated by dephosphorylizationof enzyme by
Phosphoprotein Phosphatases
Reversible inhibition of enzymes by Competitive inhibitors
Competitive inhibitors
1. Competitive inhibitors competes with substrate for binding to active site but once bound substrate cannot be transformed into product by enzymes.
2. Inhibition by Competitive inhibitors can be reversed by simply increasing concentration of substrate
3. Competitive inhibitors resembles the normal substrate in 3D structure
4. E + I = EI
NO PRODUCT FORMATION
Comparison of competitive and non-competitive inhibition Competitiveinhibitorsresembles the normal substrate in 3D structure &non-Competitiveinhibitors don’t resembles the normal substrate in 3D structure
COMPETITIVE INHIBITION ---Competitive inhibitors1 .competes with substrate for binding to active site but once bound substrate cannot be transformed into product by enzymes. 2.Inhibition by Competitive inhibitorscan be reversed by simply increasing concentration of substrate
Changes in Reaction Rate in presence of Competitive & Non –competitive inhibitor
Inhibition by Competitive inhibitorscan be reversed by simply increasingconcentration of substrate& that by
non -Competitive inhibitorscann’t be reversed by simply increasing substrate concentration.
Competitive inhibition
Competitive inhibitors competes with substrate for binding to active site but once bound substrate cannot be transformed by enzymes into product.
COMPETITIVE INHIBITION OF SUCCINATE DEHYDROGENASE BY FUMARATE ,MALONATE ,OXALO ACETATE
Structure of Succinic acid ,Malonic acid & oxaloacetic acid with two carboxylic acid groups (COOH )& can bind to an active site on succinate dehydrogenase –Competitive inhibitors
Clinical significance of Competitive inhibition
Clinical significance of Non competitive inhibitors
LineWeaver equation & enzyme inhibition
THERAPEUTIC USES OF COMPETITIVE INHIBITORS-Anti Cancer Therapy /Drugs for MyostheniaGravis/Antihypertensive
Non competitive Inhibition
Characteristics of Non competitive Inhibition
1. Reversible but not reversed by substrate
2. Inhibitor binds at site other than substrate binding site
3. It binds reversibly to both free enzyme & ES complex to form inactive complex EI & ESI
E + I ↔ EI
ES + I ↔ ESI
4. Inhibitors alter the conformation of E molecule so that reversible activation occurs
5. They are naturally occurring metabolic intermediates .
Non competitive inhibition
Threonine lsoleucine ( Threonine Dehydratase inhibited by isoleucine-final product of cascade /pathway ) -feed back inhibition
Comparison between competitive & Non competitive inhibition
Criteria competitive Non competitive
Active on Active site May or may not be active at binding site
Structure of inhibitors Substrate analogs Unrelated molecules
Inhibition reversible Generally irreversible
Excess of substrate Inhibition relieved No effect
Km Increased in presence of inhibitor
Unchanged in presence of inhibitor
Vmax Unchanged decreased
Significance Therapeutic application Toxicological application
Comparison between competitive & Non competitive inhibition
Competition inhibition –Vmax unchanged & Km INCREASEDNon competitive inhibition –Vmax decreased & Km not altered
Comparison between competitive & non competitive inhibition
Catalytic site
Regulatory site
Isoleucine Binds toregulatory site onThreonine Dehydratase & functions as non-competitive inhibitor
Mechanism of action of Aspirin
Uncompetitive inhibition of enzymes
Uncompetitive inhibition- inhibitors binds to ES ComplexVmax & Km decreased eg Alkaline Phosphatase by phenylalanine
Suicide InhibitionProperties of Suicide Inhibition
1. Irreversible inhibition
2. More effective inhibitor
3. synthesized with the help of enzyme
4. Inhibition of xanthine oxidase by Allopurinol (treatment of GOUT )
5. Alloxanthine synthesized by xanthine oxidase using Allopurinol is more potent inhibitor of enzyme than Allopurinol
6. Arachidonic acid Prostaglandin ( cyclo oxygenase )is inhibited by Aspirin.(anti inflammatory )
7. 5 Fluoro-Uracil 5 Fluoro Deoxy Uridylate more potent inhibitor of Thymidylate synthase to inhibit nucleotide synthesis and is being used in cancer treatment
Properties of Suicide inhibition
Suicide Inhibition of Allopurinol
Mechanism of action of 5-Fluorouracil
Competitive inhibitors-Therapeutic usesInhibitor (drug ) Enzyme inhibited Disease treated
Allopurinol Xanthine Oxidase Gout
Epidrene (MAO INHIBITOR )
Mono Amino Oxidase Psychiatric Treatment
Succinyl CoA Acetyl CoA Anesthesia
Dicumarol VITAMIN K EPIOXIDE REDUCTASE ANTICOAGULANT
Lovastatin HMG CoA reductase Reducing Cholesterol levels
INH ( Isonicotinic acid hydrazide )
Pyridoxal phosphate Tuberculosis
Neostigmine Acetyl Choline Esterase Myasthenia Gravis
Alpha Methyl Dopa Dopa Carboxylase Myasthenia Gravis
Competitive inhibitors-Therapeutic usesInhibitor (drug ) Enzyme inhibited Disease treated
Penicillin Trans peptidase bactericidal
Sulphonamide ( analog PABA ) Steroid synthatase Bactericidal
Trimethoprim FH2 reductase bactericidal
Pyri methamine FH2 reductase bactericidal
Methotrexate FH2 reductase Leukemia
6 –Mercapto purine Adenylo Succinate Synthtase Cancer
5 –Fluoro Uracil Thymidylate Synthtase Cancer
Azo Serine Phospho Ribosyl Amido Transferase Cancer
Cytosine Arabinoside DNA Polymerase Cancer
ACYCLOVIR DNA Polymerase Cancer
Therapeutic usesOf enzyme inhibitors